Common Contracts
6 similar Letter Agreement contracts by Icosavax, Inc.
ICOSAVAX, INC.Letter Agreement • July 22nd, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Washington
This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement, dated August 15, 2019 (the “Prior Agreement”), by and between Icosavax, Inc. (the “Company”) and you (also referred to herein as “Employee” and together, the “Parties”). This Agreement sets forth the terms of your continued employment with the Company, effective as of the closing of the Company’s initial public offering (“IPO”). In consideration of the mutual promises herein contained, the Parties agree as follows:
ICOSAVAX, INC.Letter Agreement • July 22nd, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Washington
This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement, dated August 15 2019 (the “Prior Agreement”), by and between Icosavax, Inc. (the “Company”) and you (also referred to herein as “Employee” and together, the “Parties”). This Agreement sets forth the terms of your continued employment with the Company, effective as of the closing of the Company’s initial public offering (“IPO”). In consideration of the mutual promises herein contained, the Parties agree as follows:
ICOSAVAX, INC.Letter Agreement • July 22nd, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • California
This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement, dated May 25, 2021 (the “Prior Agreement”), by and between Icosavax, Inc. (the “Company”) and you (also referred to herein as “Employee” and together, the “Parties”). This Agreement sets forth the terms of your continued employment with the Company, effective as of the closing of the Company’s initial public offering (“IPO”). In consideration of the mutual promises herein contained, the Parties agree as follows:
ICOSAVAX, INC.Letter Agreement • July 22nd, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Washington
This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement, dated August 15, 2019, as amended by that certain amendment dated January 1, 2020, as further amended by that certain amendment dated April 1, 2020 (together, the “Prior Agreement”), by and between Icosavax, Inc. (the “Company”) and you (also referred to herein as “Employee” and together, the “Parties”). This Agreement sets forth the terms of your continued employment with the Company, effective as of the closing of the Company’s initial public offering (“IPO”). In consideration of the mutual promises herein contained, the Parties agree as follows:
ICOSAVAX, INC.Letter Agreement • July 22nd, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Washington
This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement, dated October 30, 2019, as amended by that certain amendment dated February 8, 2021 (together, the “Prior Agreement”), by and between Icosavax, Inc. (the “Company”) and you (also referred to herein as “Employee” and together, the “Parties”). This Agreement sets forth the terms of your continued employment with the Company, effective as of the closing of the Company’s initial public offering (“IPO”). In consideration of the mutual promises herein contained, the Parties agree as follows:
ICOSAVAX, INC.Letter Agreement • July 22nd, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Washington
This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement, dated August 15, 2019, as amended and restated by that certain employment letter agreement, dated May 11, 2020, as amended by that certain amendment dated February 10, 2021 (together, the “Prior Agreement”), by and between Icosavax, Inc. (the “Company”) and you (also referred to herein as “Employee” and together, the “Parties”). This Agreement sets forth the terms of your continued employment with the Company, effective as of the closing of the Company’s initial public offering (“IPO”). In consideration of the mutual promises herein contained, the Parties agree as follows:
